Ecuador vs Singapore: Access to anti-retroviral drugs, male
Ecuador
87.0%
in 2024
Singapore
86.0%
in 2023
Ecuador rank
27th
Singapore rank
30th
Access to anti-retroviral drugs, male over time
- Ecuador
- Singapore
How they compare
Ecuador currently reports 87.0% against 86.0% in Singapore, a difference of 1.0%.
Across all 24 years both countries report, Singapore has been ahead every year.
Ecuador ranks 27th and Singapore ranks 30th of 141 countries.
Singapore has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Ecuador | Singapore | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 5.2% | 18.5% | 13.3% | Singapore |
| 2010s | 37.9% | 71.2% | 33.3% | Singapore |
| 2020s | 78.0% | 85.2% | 7.2% | Singapore |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Ecuador or Singapore?
- Ecuador, at 87.0% against 86.0% in Singapore as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Ecuador and Singapore?
- 1.0%, with Ecuador ahead.
- How many years of comparable data are there for Ecuador and Singapore?
- 24 years are reported by both, from 2000 to 2023.
- How do Ecuador and Singapore rank globally for access to anti-retroviral drugs, male?
- Ecuador ranks 27th and Singapore ranks 30th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.